Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31411304 | 0.80 | MAPT (0.40) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL26551200 | 0.75 | KMT2A (0.40) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL31411280 | 0.74 | KMT2A (0.45) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL31411482 | 0.74 | TSHR (0.43) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL31411468 | 0.74 | SLC9A1 (0.42) | MAPTKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL31411455 | 0.71 | MAPT (0.43) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31093775 | 0.69 | KMT2A (0.37) | MAPTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL26551198 | 0.68 | KMT2A (0.46) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL31093875 | 0.68 | KMT2A (0.38) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL26654876 | 0.68 | ALDH1A1 (0.40) | MAPTKMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | MAPT 139/4885KMT2A 2336/4885MEN1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.